RxDoctor Payments Data

Rosanna Eang, DO

Family Medicine · Camden, NJNPI 1366857997

Payments from drug & device makers

$431in general payments, 2019–2025

Across 24 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$116
  • Lilly USA, LLC$109
  • Astellas Pharma US Inc$82
  • Novo Nordisk$40
  • AbbVie$25
  • Boston Scientific$15
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$431 in reported general payments places this provider in the 50th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$44,421
Medicare patients
123
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin179$154,595
OzempicSemaglutide83$91,606
JanuviaSitagliptin Phosphate73$68,768
TrulicityDulaglutide41$57,735
EliquisApixaban55$43,634
JanumetSitagliptin Phos/Metformin Hcl31$27,487
FarxigaDapagliflozin Propanediol25$22,974
Breo ElliptaFluticasone/Vilanterol35$14,031
Bydureon BciseExenatide Microspheres17$13,686
TradjentaLinagliptin21$11,351
Janumet XrSitagliptin Phos/Metformin Hcl30$10,826
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$9,721
EntrestoSacubitril/Valsartan12$8,104
Potassium Chloride81$7,828
Lantus SolostarInsulin Glargine,hum.Rec.Anlog77$7,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$91,60683 claims
Lilly USA, LLCTrulicity$109$57,73541 claims
PfizerEliquis$15$43,63455 claims
GSKBreo Ellipta, Incruse Ellipta$116$18,59348 claims
AbbVieRestasis$25$7,14611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →